• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » AMRI, GE Healthcare extend long term supply relationship

AMRI, GE Healthcare extend long term supply relationship

December 10, 2012
CenterWatch Staff

AMRI, a global contract research and manufacturing organization, has extended its commercial supply relationship with GE Healthcare for Aminobisamide Hydrochloride (ABA).

The new contract extends through December 31, 2016, and replaces the existing supply contract between GE and AMRI that has been in effect since 2005. AMRI will supply ABA, an intermediate material used in diagnostic imaging agents. This substantial contract commitment positions AMRI as a strategic supplier to GE Healthcare. Production will continue at AMRI's large scale manufacturing subsidiary located in Rensselaer, N.Y.

"We are pleased to once again extend our long-term relationship with GE Healthcare," said Thomas E. D'Ambra, Ph.D., chairman, CEO and president of AMRI. "The renewal of this relationship underscores the confidence that premier global pharmaceutical and health care companies have in AMRI's ability to meet their critical product needs.”

D'Ambra continued, "The ABA product relationship with GE Healthcare has been an important one for AMRI since acquisition of the Rensselaer plant in 2003 and at this time is our largest commercial supply arrangement. The extension of this key, long term agreement provides a consistent and high quality revenue source for this business unit through 2016."

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing